Skip to main content

Table 1 Baseline characteristics

From: The effect of prophylactic hemoclips on the risk of delayed post-endoscopic mucosal resection bleed for upper and lower gastrointestinal lesions: a retrospective cohort study

 ClipNo Clipp value
Number of lesions337 (51%)320 (49%)N/A
Age [years, Mean (SD)]b63.83 (10.75)64.38 (11.43)0.5281
Sexb  0.5707
 Male179 (53%)176 (55%) 
 Female158 (47%)144 (45%) 
Lesion size [mm, Mean (SD)]23.13 (14.90)27.10 (23.13)<  0.001
Lesion location  0.0894
 Upper98 (29%)74 (23%) 
 Lower239 (71%)246 (77%) 
Medicationsb
 Aspirin62 (18.3%)56 (17.5%)0.7903
 NSAIDs31 (9.3%)20 (6.1%)0.1209
 Anti-platelets6 (1.8%)16 (5.1%)0.0209a
 Anti-coagulants12 (3.6%)9 (2.9%)0.5968a
Final pathologic diagnosis
 Adenoma186 (55.19%)196 (61.25%)0.1157
 Hyperplastic18 (5.34%)10 (3.13%)0.1598
 Serrated Adenoma37 (10.98%)29 (9.06%)0.4140
 Adenocarcinoma17 (5.04%)36 (11.25%)0.0035
 Hamartoma1 (0.30%)0 (0.00%)> 0.9999
 Barrett’s5 (1.48%)10 (3.13%)0.1592
 Barrett’s Carcinoma4 (1.19%)5 (1.56%)0.7466
 Pancreatic Heterotopia5 (1.48%)1 (0.31%)0.2175
 Neuroendocrine/Carcinoid Tumor28 (8.31%)8 (2.50%)0.0011
 Gastric Heterotopia of Rectum1 (0.30%)0 (0.00%)> 0.9999
 Gastrointestinal Stromal Tumor6 (1.78%)1 (0.31%)0.1239
 Granular Cell Tumor1 (0.30%)5 (1.56%)0.1145
 Gastric Intestinal Metaplasia5 (1.48%)2 (0.63%)0.4517
 Leiomyoma2 (0.59%)1 (0.31%)> 0.9999
 Inflammatory4 (1.19%)2 (0.63%)0.6867
 Lipoma6 (1.78%)3 (0.94%)0.5061
 Squamous Cell Carcinoma0 (0.00%)2 (0.63%)0.2368
 Hemangioma3 (0.89%)0 (0.00%)0.2494
 Brunner’s Gland Hyperplasia1 (0.30%)1 (0.31%)> 0.9999
 Other7 (2.08%)8 (2.50%)0.7168
  1. aAnti-platelets and anti-coagulants are usually discontinued prior to EMR in majority of cases performed at the medical centers included although this information could not be adequately captured.
  2. bDescriptive analyses for patients’ age, gender, and medication usage were performed at the patient/procedure level rather than lesion level.